NEW YORK, July 9 – Index Ventures has closed a new $300 million fund to target information technology and life sciences companies in Europe, the firm said Monday.
A spokeswoman said the firm would target life science businesses developing post-genomic platforms, therapeutics, and nanotechnology.
Index, based in Geneva, Switzerland, would most likely devote about 30 percent of the fund to life science companies, the spokeswoman said. Index has invested in six or seven biotechnology companies in the past, including Genmab, a developer of fully-human antibodies based in Copenhagen, Denmark, and Cellzome, a functional proteomics company based in Heidelberg, Germany.
With the current fund, Index Ventures II, the firm will focus slightly more heavily on life sciences than in the past, according to the company. Index now has a four-person team devoted to identifying early-stage life science companies.
Index invests primarily in European companies, but does consider US and Israeli companies that have early intentions to expand into Europe, or have strategic partnerships with European companies.
Investors in the current fund include UBS Capital, LGT Capital Partners, HarbourVest, and Standard Life Investments.